A new modeling analysis by AstraZeneca, IMPACT CKD, predicts that up to 16.5% of the population in eight countries will be affected by chronic kidney disease (CKD) by 2032, including up to 59.3% in advanced stages. Includes an increase.¹ The study, presented at the 2024 ISN World Congress of Nephrology (WCN’24) in Buenos Aires, highlights an urgent and growing global health crisis with serious economic and environmental implications.¹ IMPACT CKD is available in the United States, Brazil, United Kingdom, Spain, Germany, Netherlands, China, and Australia.¹

The study estimates that across these countries nearly 125 million people will suffer from advanced CKD by 2032, a 25% increase compared to 2022, when the model started.¹ The economic burden of renal replacement therapies, including dialysis and transplantation, is expected to reach approximately $186 billion, and dialysis requirements are expected to surge by more than 75%, contributing significantly to healthcare’s carbon footprint. This is equivalent to the carbon dioxide emissions of approximately 17.3 million cars. CO2 emissions.¹

Ruud Dobber, Executive Vice President of AstraZeneca’s Biopharmaceuticals Business Unit, emphasized: However, this future is not inevitable. At AstraZeneca, we are committed to working with global policymakers to reduce the global impact of late-stage CKD and promote early diagnosis and treatment to slow or stop disease progression. . ”

The IMPACT CKD study is part of AstraZeneca’s CKD initiative, Accelerated Change Together (ACT), which aims to improve the understanding and outcomes of CKD around the world. Through the ACT on CKD programme, AstraZeneca has launched the ‘Making Change for Kidney Health’ campaign in collaboration with the Global Patient Alliance for Kidney Health (GloPAKH). This initiative aims to put CKD on the global policy agenda and advocates comprehensive and effective disease management strategies to combat this growing health challenge.

Note

C.K.D.
CKD is a serious, progressive condition defined by a decline in kidney function (as indicated by a decline in eGFR or kidney damage markers, or both, for at least 3 months).² Approximately 850 million people worldwide are affected by CKD.³ The majority are undiagnosed.² The most common causes of CKD are diabetes, hypertension, and glomerulonephritis.^.Four CKD is associated with significant patient morbidity and increased risk of cardiovascular (CV) events, such as heart failure (HF), leading to early mortality.^Five In the most severe condition, known as kidney failure, kidney damage and decline in kidney function progresses to the point where dialysis or kidney transplantation is required.^.6 The majority of CKD patients die from CV before they reach renal failure.^{. 7}

Impact CKD
IMPACT CKD is an innovative study that incorporates sophisticated simulation models to uncover a holistic projection of the wide-ranging impact of chronic kidney disease (CKD) across clinical, economic, social, and environmental dimensions.¹ This ground-breaking analysis provides the first-ever 10-year outlook on the impact of CKD, providing insight into the US, Brazil, UK, Spain, Germany, Netherlands, China and Australia.¹ This study highlights the critical importance of early detection and treatment of CKD and provides strategic insights aimed at significantly reducing the multifaceted burden of this disease.¹

Tackle CKD
ACT on CKD is AstraZeneca’s program to transform kidney health through partnerships that aim to reduce the rate of patients progressing to kidney failure by 20% by 2025. To achieve this goal, the program supports initiatives aimed at raising awareness of the burden of CKD. and, in turn, expand early detection and drive treatment optimization to improve patient outcomes. To further support people at risk of CKD, we are also working to achieve sustainable change through health policy reform.

We want to give patients, healthcare professionals (HCPs), and decision makers the information they need to drive change. As part of our broader contribution to building knowledge about CKD, we continue to generate evidence that helps advance clinical practice. DISCOVER-CKD demonstrates the lack of urinary albumin-creatinine ratio (UACR) testing and Kidney Disease Overall Outcome Improvement (KDIGO) compliance. Guidelines. REVEAL-CKD demonstrates the extent of the gap in early detection of CKD and the clear benefits of early diagnosis. INSIDE-CKD demonstrates the future unsustainable burden of CKD and the potential benefits to health systems from improved management. PACE-CKD shows that CKD is associated with decreased quality of life not only for patients but also for their caregivers. IMPACT CKD provides modeling of future CKD burden for public health policy planning, including social and environmental impacts.

World Congress of Nephrology (WCN)
The World Congress of Nephrology (WCN) is the annual scientific, educational, and networking conference of the International Society of Nephrology (ISN).⁸ ISN is a global professional organization dedicated to advancing kidney health around the world through education, grants, research, and advocacy since 1960.^.8

AstraZeneca in CVRM
Cardiovascular, renal and metabolic (CVRM), part of the biopharmaceuticals portfolio, forms one of AstraZeneca’s key disease areas and is a key growth driver for the company. By following science to more clearly understand the underlying connections between the heart, kidneys, liver and pancreas, AstraZeneca can help protect organs by slowing or stopping disease progression and ultimately develop regenerative therapies. We are investing in a portfolio of medicines that pave the way for The company’s goal is to better understand the interrelationships between CVRM diseases and target the mechanisms that cause CVRM diseases so that they can be detected, diagnosed and treated earlier and more effectively. , to improve and save the lives of millions of people.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-driven biopharmaceutical company focused on prescription drug discovery in biopharmaceuticals, including oncology, rare diseases, cardiovascular, renal and metabolic, and respiratory; We are focusing on development and commercialization. & Immunology. Based in Cambridge, England, AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients around the world. Visit astrazeneca.com and follow us on social media @AstraZeneca.

contact
Click here for more information on how to contact our Investor Relations team. Click here for media contact information.